$NEO

Aunan Greg D sold $321K of NEO

Aunan Greg D (Chief Accounting Officer) sold 20,000 shares of NEOGENOMICS INC (NEO) at $16.07 ($0.32M total) on 2026-08-04.

Original reporting
SEC EDGAR · Aunan Greg D
Published Aug 6, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 7, 2026, 7:45 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NEO
Neutral
low confidence
Mentioned
$NEO
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NEONeutralLow
01

Why it matters

A single officer open-market sale can modestly affect sentiment, but it is not a fundamental datapoint like earnings, guidance, or a deal.

02

Market read

Traders may note the insider sale for sentiment, but there is no additional company-specific catalyst in the text.

03

What to watch

The filing does not include motives, and the post-sale holdings (5,153 shares) suggest the sale may be part of routine personal liquidity rather than a large conviction shift.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-06 for a sale dated 2026-08-04

Background

The article is an SEC Form 4 insider transaction disclosure for NEOGENOMICS.

Company-level read

Ticker impact

$NEONeutralLow confidence
Context

NEOGENOMICS insider Aunan Greg D sold 20,000 shares at $16.07 on 2026-08-04, per a newly filed Form 4.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and typically fades unless paired with other disclosures.

Evidence & confidence

Form 4 provides transaction details but no accompanying company-specific catalyst, guidance change, or regulatory/legal event.

Market effects

No clear sector read-through from a single insider sale.

None.

None.

Counterpoint

Insider sales are often planned for diversification or tax needs; the absence of a stated 10b5-1 plan does not automatically imply negative information.

Key entities

  • NEOGENOMICS INC

    Subject of the Form 4 insider transaction disclosure.

  • Aunan Greg D

    Chief Accounting Officer who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NEOMed

Piper Sandler reiterates Neogenomics stock rating on service strength

Piper Sandler reiterated an Overweight rating on Neogenomics (NEO), citing its competitive position in the community oncology lab market. The firm highlighted the company's service and menu offerings, with NEO ranking first in menu completeness, turnaround, and service. NEO's stock has fallen 10% to $16.42, despite an 83% return over the past year. Recent earnings exceeded expectations, with adjusted earnings of $0.05 per share and revenue of $202 million.

$NEOMed

Why NeoGenomics (NEO) Stock Is Up Today

NeoGenomics (NEO) shares rose 3.6% premarket after announcing an executive succession plan and preliminary Q3 revenue of $209M, with next-gen sequencing revenue up 28% YoY. The company expects to raise full-year guidance. BTIG upgraded NEO to Buy with a $28 price target. Shares later fell to $17.36, down 9.1% from the previous close.

$LENHighAI 8/10

Stocks making the biggest moves premarket: Constellation Energy, Option Care Health, Lennar, P&G and more

Constellation Energy (CEG) surged 6% after Google's $4.3B power agreement. Option Care Health (OPK) rose 20% on potential $5B acquisition by McKesson (MCK) and Clayton Dubilier. Lennar (LEN) gained 1.5% after Berkshire Hathaway (BRK.A) disclosed a 2.4M share purchase. NeoGenomics (NEO) climbed 5% on revenue beat and succession plan. AMD (AMD) rose 2% on Citi's $800 price target. P&G (PG) up 1.2% after Evercore ISI upgrade. Corteva (CTVA) gained 3% on JPMorgan upgrade.